Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02634827 · ClinicalTrials.gov registry record · Phase 2
Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02634827: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT02634827 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02634827, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase II trial studies how well midostaurin and decitabine work in treating older patients with newly diagnosed acute myeloid leukemia and FLT3 mutations. Midostaurin and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Decitabine
- OTHER Laboratory Biomarker Analysis
- DRUG Midostaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-12-30 |
| Est. Completion | 2018-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02634827
The ClinicalTrials.gov registry entry for NCT02634827 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Decitabine is the first listed.
NCT02634827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02634827 about?
NCT02634827 is a clinical study titled "Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation". This phase II trial studies how well midostaurin and decitabine work in treating older patients with newly diagnosed acute myeloid leukemia and FLT3 mutations. Midostaurin and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02634827?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2015-12-30. Estimated completion is 2018-06-12.
What interventions are being tested in trial NCT02634827?
The interventions under investigation include: Decitabine (DRUG), Laboratory Biomarker Analysis (OTHER), Midostaurin (DRUG).
Who is sponsoring clinical trial NCT02634827?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.